Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9030628 | 0.83 | TBXAS1 (0.71) | TBXAS1 | |
| SCHEMBL9030728 | 0.83 | TBXAS1 (0.71) | TBXAS1 | |
| SCHEMBL9030641 | 0.83 | TBXAS1 (0.71) | TBXAS1 | |
| SCHEMBL7810685 | 0.82 | TBXAS1 (0.46) | TBXAS1NPC1RAB9AHTR7HTR1A | |
| SCHEMBL11994148 | 0.82 | HTR7 (0.50) | TBXAS1HTR7ESR2ESR1 | |
| SCHEMBL16685238 | 0.82 | ESR1 (0.46) | TBXAS1BCL2L1ESR2ESR1 | |
| SCHEMBL14288473 | 0.81 | ESR1 (0.52) | TBXAS1HTR7ESR2ESR1 | |
| SCHEMBL5089367 | 0.81 | TBXAS1 (0.48) | TBXAS1NPC1RAB9AHTR7HTR1A | |
| SCHEMBL28304994 | 0.79 | TBXAS1 (0.63) | TBXAS1SIGMAR1 | |
| SCHEMBL5679037 | 0.78 | TBXAS1 (0.67) | TBXAS1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | UNIV TEXAS TECH SYSTEM (US) | 2025-05-15 | — | — | US | disclosed |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2023-11-30 | — | — | US | disclosed |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TEXAS TECH UNIVERSITY SYSTEM (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338204-B2 | Substituted bisphenylalkylurea compounds and methods of treating breast cancer | TP53, ULK1, TFEB | TBXAS1 2469/4885NPC1 903/4885RAB9A 658/4885 |
| US-20210309607-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | TBXAS1 2469/4885NPC1 903/4885RAB9A 658/4885 |
| US-20230382850-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING INFLAMMATORY CONDITIONS | TFEB, TP53, BECN1 | TBXAS1 2069/4885NPC1 1346/4885RAB9A 1019/4885 |
| US-20250154098-A1 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | TP53, ULK1, TFEB | TBXAS1 2469/4885NPC1 903/4885RAB9A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.